Amarin Corporation plc (NASDAQ:AMRN): According to JPMorgan, there is a strong liklihood that the FDA will approve Amarin’s AMR101 on the July 26 action date, and the firm believes shares may rally into the high teens/low twenties on approval. The firm thinks AMR101 reflects a possible $1 billion plus product opportunity, and it maintains an Overweight rating on the stock.
Don’t Miss: Apple’s Phantom iPhone Has a Ton of Buyers.
Amazon.com Inc. (NASDAQ:AMZN) is expected by Bernstein to beat the consensus Q2 EPS estimate, mainly because of gross profit margin expansion. The firm keeps an Outperform rating and a $251 price target on the stock.
Citrix Systems, Inc. (NASDAQ:CTXS) is predicted by Bernstein to report stronger Q2 results than expected, since the firm expects the company to benefit from a higher capex at public cloud companies. The firm keeps an Outperform rating and a $106 price target on the stock.
Xerox Corp.’s (NYSE:XRX) reduced 2012 outlook may actually help the stock’s performance since it has traded better historically with lower expectations. Shares have a Buy rating, but the price target was reduced to $8.50 from $9.00.
Cree Inc.’s (NASDAQ:CREE) estimates and price targets were reduced due to a more conservative view concerning LED lighting adoption as well as weaker pricing expectations. The firm predicts that June’s quarter results will meet expectations, and the firm keeps a Buy rating on the stock.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.